Skip to content
Bored Studies
RecruitingPhase 1

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

Climb Bio, Inc. · NCT07011043

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–65 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 1
Target enrollment
30
US sites recruiting
2
Study start
July 10, 2025
Record last updated
March 27, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.

Being studied: Budoprutug

Conditions: Systemic Lupus Erythematosus

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Aged 18 to 65 years at the time of consent.
  • Diagnosis of SLE according to the 2019 European League Against. Rheumatism and the American College of Rheumatology (ACR) classification criteria.
  • Active, seropositive disease, with SLEDAI 2K >=8.
  • Inadequate response to at least 2 therapeutic interventions, including at least one oral immunosuppressive or biologic standard-of care therapy.

Exclusion Criteria

  • Active neuropsychiatric SLE.
  • History of inflammatory or autoimmune diseases including, but not limited to, rheumatoid arthritis, scleroderma, myositis, vasculitis, inflammatory bowel disease, or other conditions that require immune suppressive therapy. Subjects with stable concurrent Sjogren's, asthma, or autoimmune thyroid disease may be considered for participation.
  • Active systemic infection or history of chronic, recurrent, latent, or recent serious infections.

Recruiting US locations

Study contacts (from the official record)

  • Climb Bio Study Director · +1 866 857 2596 · clinicaltrials@climbbio.com
All phase 1 studies in Texas →
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) (NCT07011043) | Bored Studies